Telo Genomics: TELO-MRD detects circulating malignant plasma cells in all clonoSEQ-positive myeloma cases reviewed

The company says its blood-based TELO-MRD test detected circulating malignant plasma cells in all bone-marrow NGS MRD-positive cases reviewed, and in some cases deemed MRD-negative or non-evaluable by the NGS method; TELO-MRD targets a commercial application by end-2027.